These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 22018611)
1. Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. Larenas-Linnemann DE; Pietropaolo-Cienfuegos DR; Calderón MA Ann Allergy Asthma Immunol; 2011 Nov; 107(5):407-416.e11. PubMed ID: 22018611 [TBL] [Abstract][Full Text] [Related]
2. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Larenas-Linnemann D; Blaiss M; Van Bever HP; Compalati E; Baena-Cagnani CE Ann Allergy Asthma Immunol; 2013 Jun; 110(6):402-415.e9. PubMed ID: 23706708 [TBL] [Abstract][Full Text] [Related]
3. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. Calderon MA; Casale TB; Nelson HS; Demoly P J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829 [TBL] [Abstract][Full Text] [Related]
4. 3-years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. Dominicus R Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):135-40. PubMed ID: 22905596 [TBL] [Abstract][Full Text] [Related]
5. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188 [TBL] [Abstract][Full Text] [Related]
7. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635 [TBL] [Abstract][Full Text] [Related]
8. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407 [TBL] [Abstract][Full Text] [Related]
9. Treatment of respiratory allergy with allergy immunotherapy tablets. Bachert C Allergy; 2011 Jul; 66 Suppl 95():57-9. PubMed ID: 21668858 [TBL] [Abstract][Full Text] [Related]
10. [Analysis of the efficacy of specific immunotherapy with house-dust mite extracts in adults with allergic rhinitis and/or asthma]. Polzehl D; Keck T; Riechelmann H Laryngorhinootologie; 2003 Apr; 82(4):272-80. PubMed ID: 12717603 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic efficacy of 3-year subcutaneous immunotherapy in asthmatic children allergic to mite]. Li L; Hui Y; Qian J; Guo Y; Zhang XL; Zhang XJ Zhongguo Dang Dai Er Ke Za Zhi; 2013 May; 15(5):368-71. PubMed ID: 23676940 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368 [TBL] [Abstract][Full Text] [Related]
13. Towards evidence-based medicine in specific grass pollen immunotherapy. Calderon M; Mösges R; Hellmich M; Demoly P Allergy; 2010 Apr; 65(4):420-34. PubMed ID: 20028374 [TBL] [Abstract][Full Text] [Related]
14. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684 [TBL] [Abstract][Full Text] [Related]
16. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite. Baris S; Kiykim A; Ozen A; Tulunay A; Karakoc-Aydiner E; Barlan IB Allergy; 2014 Feb; 69(2):246-53. PubMed ID: 24180595 [TBL] [Abstract][Full Text] [Related]
17. New visions in specific immunotherapy in children: an iPAC summary and future trends. Halken S; Lau S; Valovirta E Pediatr Allergy Immunol; 2008 Aug; 19 Suppl 19():60-70. PubMed ID: 18665964 [TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Pokladnikova J; Krcmova I; Vlcek J Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082 [TBL] [Abstract][Full Text] [Related]
19. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Mondoulet L; Dioszeghy V; Ligouis M; Dhelft V; Dupont C; Benhamou PH Clin Exp Allergy; 2010 Apr; 40(4):659-67. PubMed ID: 20002446 [TBL] [Abstract][Full Text] [Related]
20. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Eng PA; Borer-Reinhold M; Heijnen IA; Gnehm HP Allergy; 2006 Feb; 61(2):198-201. PubMed ID: 16409196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]